Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States

David D. Stenehjem; Solomon J. Lubinga; Komal Gupte-Singh; Ying Zhang; Trong Kim Le; John R. Penrod; Cardinale B. Smith

doi:10.1016/j.cllc.2020.07.009

Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States

David D. Stenehjem, Solomon J. Lubinga, Komal Gupte-Singh, Ying Zhang, Trong Kim Le, John R. Penrod, Cardinale B. Smith

Duluth Pharmacy Program

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.

Original language	English (US)
Pages (from-to)	e35-e47
Journal	Clinical Lung Cancer
Volume	22
Issue number	1
DOIs	https://doi.org/10.1016/j.cllc.2020.07.009
State	Published - Jan 2021

Bibliographical note

Funding Information:
This study was supported by Bristol Myers Squibb. D.D.S. reports research funding to his institution from Bristol Myers Squibb, Novartis, AstraZeneca, and Bioverativ, and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.Medical writing assistance was provided by Roland Tacke, PhD, Evidence Scientific Solutions, funded by Bristol Myers Squibb.

Funding Information:
This study was supported by Bristol Myers Squibb . D.D.S. reports research funding to his institution from Bristol Myers Squibb , Novartis, AstraZeneca, and Bioverativ , and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.

Publisher Copyright:
© 2020 The Authors

Keywords

Advanced age
Observational study
Overall survival
Performance status
Progression-free survival

PubMed: MeSH publication types

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.cllc.2020.07.009

OpenUrl availability

Full text

Cite this

@article{e95afd05070a43b784ae3dcb47b17a98,

title = "Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States",

abstract = "In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.",

keywords = "Advanced age, Observational study, Overall survival, Performance status, Progression-free survival",

author = "Stenehjem, {David D.} and Lubinga, {Solomon J.} and Komal Gupte-Singh and Ying Zhang and Le, {Trong Kim} and Penrod, {John R.} and Smith, {Cardinale B.}",

note = "Funding Information: This study was supported by Bristol Myers Squibb. D.D.S. reports research funding to his institution from Bristol Myers Squibb, Novartis, AstraZeneca, and Bioverativ, and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.Medical writing assistance was provided by Roland Tacke, PhD, Evidence Scientific Solutions, funded by Bristol Myers Squibb. Funding Information: This study was supported by Bristol Myers Squibb . D.D.S. reports research funding to his institution from Bristol Myers Squibb , Novartis, AstraZeneca, and Bioverativ , and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2021",

month = jan,

doi = "10.1016/j.cllc.2020.07.009",

language = "English (US)",

volume = "22",

pages = "e35--e47",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States

AU - Stenehjem, David D.

AU - Lubinga, Solomon J.

AU - Gupte-Singh, Komal

AU - Zhang, Ying

AU - Le, Trong Kim

AU - Penrod, John R.

AU - Smith, Cardinale B.

N1 - Funding Information: This study was supported by Bristol Myers Squibb. D.D.S. reports research funding to his institution from Bristol Myers Squibb, Novartis, AstraZeneca, and Bioverativ, and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.Medical writing assistance was provided by Roland Tacke, PhD, Evidence Scientific Solutions, funded by Bristol Myers Squibb. Funding Information: This study was supported by Bristol Myers Squibb . D.D.S. reports research funding to his institution from Bristol Myers Squibb , Novartis, AstraZeneca, and Bioverativ , and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals. Publisher Copyright: © 2020 The Authors

PY - 2021/1

Y1 - 2021/1

N2 - In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.

AB - In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.

KW - Advanced age

KW - Observational study

KW - Overall survival

KW - Performance status

KW - Progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85095947448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095947448&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.07.009

DO - 10.1016/j.cllc.2020.07.009

M3 - Article

C2 - 33187914

AN - SCOPUS:85095947448

SN - 1525-7304

VL - 22

SP - e35-e47

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 1

ER -

Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this